Active macrophage membrane coated miRNA nano delivery system and preparation method thereof

By loading miR-451a on the metal organic framework ZIF-8 and wrapping the anti-inflammatory M2 macrophage membrane to form the M@ZIF-8@miR delivery system, the existing vector stability and low cell uptake rate were solved, and the problem of existing vector stability and low cellular uptake rate was achieved. Efficient miR-451a delivery and release significantly inhibits inflammatory joint disease.

CN118976006APending Publication Date: 2024-11-19THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411166241.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-23
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The existing miR-451a vector has problems such as low cell uptake, lysosomal escape and biodegradation, and the immunogenicity and mutagenicity of viral vectors limit their application. The non-viral vectors have low loading rate and poor stability, making it difficult to use effectively. Treatment of inflammatory joint diseases such as hemophilia arthritis.

Method used

Using the metal organic framework ZIF-8 loaded miR-451a and wrapped by anti-inflammatory M2 macrophage membrane to form a nanoscale M@ZIF-8@miR delivery system, using the pH response decomposition characteristics of ZIF-8 in an acidic environment Release of miR promotes repolarization and inflammation inhibition of macrophages.

Benefits of technology

Achieve efficient delivery and release of miR-451a, reduces cytotoxicity, improves cell absorption, effectively inhibits synovial and angiogenesis, has low immunogenicity and high stability, and is suitable for hemophilia joints. Treatment of diseases such as inflammation and osteoarthritis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118976006A_ABST
    Figure CN118976006A_ABST
Patent Text Reader

Abstract

The invention discloses an activated macrophage membrane coated miRNA nano-delivery system and a preparation method thereof in the technical field of drug delivery systems, the nano-delivery system is expressed as M (at) ZIF-8 (at) miR, M is an M2 polarized macrophage membrane, ZIF-8 is a metal organic framework, and miR is a non-coding single-stranded RNA molecule; the nano delivery system is wrapped outside the metal organic framework through an M2 macrophage membrane, and a non-coding single-stranded RNA molecule is loaded in the metal organic framework. According to the invention, the miRs are loaded in the nano-scale ZIF-8 and are wrapped by the M2 cell membrane with an anti-inflammatory effect, and the nano delivery system has lower cytotoxicity and higher cell absorption rate, and can be decomposed in acidic endosomes / lysosomes, so that the release of the miRs is triggered.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to an activated macrophage membrane-wrapped miRNA nano delivery system and a preparation method thereof, and belongs to the technical field of drug delivery systems. Background Art

[0002] Hemophilic arthropathy (HA) is one of the most common and typical musculoskeletal complications in hemophiliacs. HA patients experience repeated intra-articular bleeding, accompanied by chronic pain, advanced fibrosis, and loss of joint function. Platelet-rich plasma (PRP) is a platelet concentrate extracted from autologous peripheral blood by centrifugation. Activated platelets can secrete a variety of growth factors and accelerate tissue regeneration, so they are widely used in the treatment of a series of musculoskeletal diseases such as osteoarthritis. However, considering the low survival and regeneration rates of platelets themselves and potential immune rejection, the use of exosomes extracted from platelets may be a better choice. Exosomes are extracellular vesicles (EVs) with a diameter between 30 and 200 nm, good biocompatibility, innate stability, and low immunogenicity. PRP-derived exosomes (PRP-exo) have advantages in cartilage protection, muscle function recovery, and tendon progenitor cell proliferation and migration.

[0003] MicroRNAs (miRs) are a class of endogenous non-coding RNAs with regulatory functions. They are about 20 to 25 nucleotides long and have a negative regulatory effect on transcription by inhibiting mRNA translation or degrading mRNA. miR-451a has the potential to alleviate synovial and vascular hyperplasia in the pathological process of HA. However, due to its low cellular uptake rate, lysosomal escape and biodegradation, miR faces obstacles in its application in HA in vivo biotherapy. The vectors of miR-451a are divided into viral vectors and non-viral vectors. Although the development of viral vectors has made breakthrough progress, its application is limited due to its immunogenicity and mutagenicity. The existing non-viral vectors also have disadvantages such as low loading rate and poor stability. Therefore, the development of a safe and efficient vector that can improve the stability of miR-451a in vivo is especially the core of treatment.

[0004] Metal-organic frameworks (MOFs) are highly porous nanomaterials self-assembled by metal ions and organic ligands. They have the characteristics of large specific surface area, high stability, adjustable pore size, site modifiable, good biocompatibility and biodegradability. Therefore, they are widely used in medical fields such as drug loading, targeted delivery and wound repair. Summary of the invention

[0005] The purpose of the present invention is to overcome the deficiencies in the prior art and provide an activated macrophage membrane-wrapped miRNA nano-delivery system and a preparation method thereof, wherein miRs are loaded into nano-scale ZIF-8 and wrapped by the anti-inflammatory M2 cell membrane, and the nano-delivery system has lower cytotoxicity and higher cell absorption rate, and can be decomposed in acidic endo / lysosomes, thereby triggering the release of miRs.

[0006] To achieve the above object, the present invention is implemented by adopting the following technical solutions: In one aspect, the present invention provides an activated macrophage membrane-encapsulated miRNA nano-delivery system, wherein the nano-delivery system is represented by M@ZIF-8@miR, wherein M is an M2 polarized macrophage membrane, ZIF-8 is a metal organic framework, and miR is a non-coding single-stranded RNA molecule; The nano delivery system is wrapped around the outside of the metal organic framework through the M2 macrophage membrane, and the metal organic framework is loaded with non-coding single-stranded RNA molecules.

[0007] Optionally, the particle size of the M2 polarized macrophage membrane ranges from 150 to 200 nm.

[0008] In another aspect, the present invention provides a method for preparing the activated macrophage membrane-encapsulated miRNA nano-delivery system as described in any one of the above, comprising: preparing a metal organic framework solution; A non-coding single-stranded RNA molecule is added to the metal organic framework solution, and the precipitate is collected after a first centrifugation operation, and ZIF-8@miR is obtained after washing; Preparation of M2 polarized macrophage membranes; The M2 polarized macrophages were re-mixed with ZIF-8@miR and then repeatedly extruded through an extruder to obtain M@ZIF-8@miR.

[0009] Furthermore, the preparation of the metal organic framework solution comprises: Dissolve dimethylimidazole in methanol and stir to obtain solution A; Dissolve zinc nitrate hexahydrate in methanol and perform ultrasonic vibration to obtain solution B; Solution A is added dropwise to solution B, and the mixture is evenly mixed to obtain a metal organic framework solution.

[0010] Furthermore, the non-coding single-stranded RNA molecule needs to be labeled or chemically modified before being added to the metal organic framework solution.

[0011] Furthermore, the washing comprises washing with double distilled water and methanol at least three times in sequence.

[0012] Furthermore, the preparation of M2 polarized macrophage membrane comprises: RAW264.7 cells in the logarithmic growth phase were co-cultured with interleukin-4 and interleukin-13 to obtain M2 polarized macrophages; After washing the M2 polarized macrophages with polybutylene succinate, the M2 polarized macrophages were suspended in a hypotonic lysis buffer; The M2 polarized macrophages were segmented and lysed using a homogenizer, the supernatant was taken for a third centrifugation operation, and the precipitate was collected to obtain the M2 polarized macrophage membrane.

[0013] Furthermore, the method further includes filtering the M2 polarized macrophage membrane through a filter to obtain the M2 polarized macrophage membrane with a particle size ranging from 150 to 200 nm; The M2 polarized macrophage membrane also needs to be quantified for protein to verify whether the lysis of the M2 polarized macrophages is successful.

[0014] Furthermore, the condition parameters of the third centrifugation operation include first centrifuging at a speed of 700-900 rpm for 8-12 min, and then centrifuging at a speed of 10000-140000 rpm for 25-35 min.

[0015] Furthermore, the condition parameters of the first centrifugal operation include a centrifugal speed of 8000-12000 rpm and a time of 8-12 min; the condition parameters of the second centrifugal operation include a centrifugal speed of 10000-14000 rpm and a time of 25-35 min.

[0016] Compared with the prior art, the present invention has the following beneficial effects: The present invention loads miRs into the nanoscale metal organic framework ZIF-8 and is wrapped by the M2 macrophage membrane with anti-inflammatory effect. The formed nano delivery system has low cytotoxicity and high cell absorption rate, and can be decomposed in acidic endosomes / lysosomes, thereby triggering the release of miRs. MiRs can effectively promote the repolarization of macrophages M1 to M2 in vivo, inhibit synovial fibroblasts and angiogenesis, and contribute to the treatment of inflammatory joint diseases such as hemophilic arthritis, osteoarthritis, rheumatoid arthritis and gouty arthritis. The nanoscale metal-organic framework ZIF-8 used in the present invention has pH-responsive decomposition characteristics, which enables it to help miRs escape into lysosomes, thereby making the delivery of miRs possible and efficient; compared with M1 macrophage membranes, M2 macrophage membranes can better downregulate the expression of inflammatory factors in inflammatory joint diseases, thereby contributing to cartilage recovery. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1A schematic diagram of a therapeutic method of a miRNA nano-delivery system encapsulated by an activated macrophage membrane in one embodiment of the present invention; Figure 2 Schematic diagram of the ability dispersion X-ray spectrum of ZIF-8@miR of the miRNA nano-delivery system encapsulated by macrophage membrane in one embodiment of the present invention. DETAILED DESCRIPTION

[0018] The present invention will be further described below in conjunction with the accompanying drawings. The following embodiments are only used to more clearly illustrate the technical solution of the present invention, and cannot be used to limit the protection scope of the present invention.

[0019] The endpoints and any values ​​of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of each range, the endpoint values ​​of each range and the individual point values, and the individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be regarded as specifically disclosed in this article.

[0020] For the purpose of this specification and the appended claims, unless otherwise stated, all numbers expressing amounts, percentages or ratios and other numerical values ​​used in this specification and the appended claims are understood to be modified in all cases by the term "about". In addition, all ranges disclosed herein are inclusive and independently combinable. Example 1

[0021] The present invention provides a method for preparing a metal organic framework solution ZIF-8, which comprises the following steps: Dissolve 325 mg of dimethylimidazole (2-MIM) in 10 mL of methanol and stir for 30 min to obtain solution A.

[0022] 147 mg of zinc nitrate hexahydrate was dissolved in 5 mL of methanol and ultrasonically shaken for 5 min to obtain solution B.

[0023] Solution A was added dropwise to solution B, and the mixture was mixed evenly to obtain a metal organic framework solution ZIF-8. Example 2

[0024] In this example, miR-451a agomir is selected as a non-coding single-stranded RNA molecule. Agomir is a chemically modified double-stranded microRNA mimic used for microRNA function research. It can mimic endogenous mature microRNA and bind to target gene mRNA to regulate its expression. Compared with ordinary microRNA mimics, agomir has higher stability and activity, and is easier to pass through cell membranes and tissue gaps and enrich in target cells.

[0025] The miR-451a agomir was labeled with fluorescent dye to obtain Cy5-miR. Example 3

[0026] On the basis of Example 1 and Example 2, miR-451a agomir labeled with fluorescent dye Cy5 was added to the metal organic framework solution ZIF-8 in an appropriate volume, centrifuged at 10000 rpm for 10 min, and then washed four times with double distilled water (ddH2O) and methanol to remove excess reactants to obtain ZIF-8@miR. Example 4

[0027] Based on Example 3, an M2 polarized macrophage membrane is prepared, comprising: RAW264.7 cells (M0) in the logarithmic growth phase were co-cultured with 20 ng / mL interleukin-4 and interleukin-13 for 24 hours to obtain M2 polarized macrophages.

[0028] After washing the M2 polarized macrophages with polybutylene succinate (PBS), the M2 polarized macrophages were suspended in a hypotonic lysis buffer. In this embodiment, the hypotonic lysis buffer contained membrane protein extraction reagent A and phenylmethylsulfonyl chloride (100:1).

[0029] The cells were divided 20 times using a homogenizer, and then the supernatant was centrifuged at 800 rpm for 10 min at -4°C and then at 1200 rpm for 30 min to collect the cell membrane fragments.

[0030] The cell membrane fragments were first filtered through a 0.45 μm filter and then through a 0.22 μm filter to obtain M2 macrophage membranes with a particle size less than 200 nm, and quantified using a BCA kit.

[0031] M2 macrophage membranes were mixed with ZIF-8@miR at a mass ratio of 1:1 and repeatedly extruded by an Avanti microextruder to obtain M@ZIF-8@miR.

[0032] The products obtained in Examples 1 to 4 are analyzed below: First, the absorbance of ZIF-8, ZIF-8@miR and M@ZIF-8@miR prepared in Examples 1, 3 and 4 at different wavelengths was characterized by UV-visible (UV-2450) to ensure successful synthesis. The UV-visible spectrum showed that ZIF-8@miR and M@ZIF-8@miR had characteristic peaks at 260nm, indicating that miR-451a was successfully loaded into the nanocomposite.

[0033] The average hydrodynamic particle size distribution and zeta potential were observed by a laser particle size analyzer (NanoBrook 90PlusPALS, Brookhaven, USA). The results showed that the average particle size of M@ZIF-8@miR was 141.3 nm, the polydispersity index was 0.291, and its hydrodynamic diameter distribution increased compared with that of bare ZIF-8, indicating successful cell membrane encapsulation. After loading miR-451a and M2 macrophage membrane packaging, the zeta potential of ZIF-8 decreased from +24.3±1.5mV to -10.6±0.6mV and -7.5±0.7mV, which further confirmed that the negatively charged miR-451a was adsorbed on the positively charged ZIF-8.

[0034] Then, the microscopic morphology of the nanoparticles was examined using SEM, TEM (Titan G2), and energy dispersive spectroscopy (EDS).

[0035] TEM images show that the nanoparticles of ZIF-8@miR have a regular polycrystalline morphology with clear edges and a size of about 100 nm. Due to the wrapping effect of the cell membrane, the size of M@ZIF-8@miR increases and becomes round.

[0036] like Figure 2 As shown in Figure 3, from the energy dispersive X-ray spectroscopy data, N and Zn (elements in ZIF-8) and P (element in miR-451a) were uniformly distributed in each particle, which further confirmed that miR-451a was successfully adsorbed on ZIF-8.

[0037] In order to quantitatively evaluate the loading capacity of miRNA on ZIF-8, different amounts of Cy5-miR prepared in Example 2 were mixed with ZIF-8 to form Cy5-miR-451a@ZIF-8 complexes. After centrifugation, the fluorescence of Cy5-miR in the supernatant was measured by fluorescence spectroscopy, showing that when the weight ratio of miR-451a to ZIF-8 was 5:70 (w / w), the loading capacity of miRNA reached the highest point.

[0038] To evaluate the stability of M@ZIF-8@miR nanocomposites in buffers with different pH values, the difference in the ability of ZIF-8@miR nanocomposites to release miRNA under conditions simulating normal physiological environments (pH 7.4) and lysosomal acidity (pH 5.5) was studied. In contrast, in neutral PBS buffer simulating physiological conditions, the amount of miRNA released at pH 7.4 was very small (no more than 49%), which confirmed the absolute encapsulation of M@ZIF-8@miR nanocomposites.

[0039] To evaluate the in vitro biological effects of M@ZIF-8@miR nanoparticles, the cytotoxicity of miRNA, ZIF-8@miR, and M@ZIF-8@miR on fibroblast-like synoviocytes and RAW264.7 cell lines was studied. The toxicity was evaluated by MTT assay. When the concentration of M@ZIF-8@miR reached 50 μg / mL, the survival rates of both cell lines were less than 80%. We used this concentration as the upper limit concentration in subsequent experiments.

[0040] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the technical principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. An activated macrophage membrane-encapsulated miRNA nano-delivery system, characterized in that: The nano-delivery system is represented as M@ZIF-8@miR, wherein M is the M2 polarized macrophage membrane, ZIF-8 is a metal organic framework, and miR is a non-coding single-stranded RNA molecule; The nano delivery system is wrapped around the outside of the metal organic framework through the M2 macrophage membrane, and the metal organic framework is loaded with non-coding single-stranded RNA molecules.

2. The activated macrophage membrane-encapsulated miRNA nano-delivery system according to claim 1, characterized in that: The particle size of the M2 polarized macrophage membrane ranges from 150 to 200 nm.

3. A method for preparing the activated macrophage membrane-encapsulated miRNA nano-delivery system as claimed in claim 1 or 2, characterized in that: include: preparing a metal organic framework solution; A non-coding single-stranded RNA molecule is added to the metal organic framework solution, and the precipitate is collected after a first centrifugation operation, and ZIF-8@miR is obtained after washing; Preparation of M2 polarized macrophage membranes; The M2 polarized macrophages were re-mixed with ZIF-8@miR and then repeatedly extruded through an extruder to obtain M@ZIF-8@miR.

4. The method for preparing the activated macrophage membrane-encapsulated miRNA nano-delivery system according to claim 3, characterized in that: The method for preparing the metal organic framework solution comprises: Dissolve dimethylimidazole in methanol and stir to obtain solution A; Dissolve zinc nitrate hexahydrate in methanol and perform ultrasonic vibration to obtain solution B; Solution A is added dropwise to solution B, and the mixture is evenly mixed to obtain a metal organic framework solution.

5. The method for preparing the activated macrophage membrane-encapsulated miRNA nano-delivery system according to claim 3, characterized in that: The non-coding single-stranded RNA molecule needs to be labeled or chemically modified before being added to the metal organic framework solution.

6. The method for preparing the activated macrophage membrane-encapsulated miRNA nano-delivery system according to claim 3, characterized in that: The washing comprises washing with double distilled water and methanol at least three times in sequence.

7. The method for preparing the activated macrophage membrane-encapsulated miRNA nano-delivery system according to claim 3, characterized in that: The method for preparing M2 polarized macrophage membrane comprises: RAW264.7 cells in the logarithmic growth phase were co-cultured with interleukin-4 and interleukin-13 to obtain M2 polarized macrophages; After washing the M2 polarized macrophages with polybutylene succinate, the M2 polarized macrophages were suspended in a hypotonic lysis buffer; The M2 polarized macrophages were segmented and lysed using a homogenizer, the supernatant was taken for a second centrifugation operation, and the precipitate was collected to obtain the M2 polarized macrophage membrane.

8. The method for preparing the activated macrophage membrane-encapsulated miRNA nano-delivery system according to claim 7, characterized in that: It also includes filtering the M2 polarized macrophage membrane through a filter to obtain the M2 polarized macrophage membrane with a particle size ranging from 150 to 200 nm; The M2 polarized macrophage membrane also needs to be quantified for protein to verify whether the lysis of the M2 polarized macrophages is successful.

9. The method for preparing the activated macrophage membrane-encapsulated miRNA nano-delivery system according to claim 7, characterized in that: The condition parameters of the second centrifugation operation include first centrifuging at a speed of 700-900 rpm for 8-12 min, and then centrifuging at a speed of 10000-140000 rpm for 25-35 min.

10. The method for preparing the activated macrophage membrane-encapsulated miRNA nano-delivery system according to claim 3, characterized in that: The condition parameters of the first centrifugation operation include a centrifugal speed of 8000-12000 rpm and a time of 8-12 min.

Citation Information

Cited By

  • Zn-Mn bimetallic ZIF material and preparation method and application thereof

    CN120518879A